Study design and population
T2D, mental illness, hypoglycemic, kidney, liver, or cardiovascular disease, diabetes
COMPLICATIONS, DIABETES
A 12-week randomized controlled trial was designed to evaluate the efficacy of Jinlida as an add-on medication in T2D. All subjects in both groups also continuously received their metformin without any dose changes. Treatment group: Jinlida granules were orally given at 9 g three times per day after meals. Control group: placebos were orally given at 9 g three times per day after meals. The eligible subjects were T2D patients who received metformin treatment for more than 3 months but HbA1c ≥ 7.0% and FPG 7.0–13.9 mmol/L or 2hPG ≥ 11.1 mmol/L. Patients who took other hypoglycemic drugs or insulin besides metformin in the past 3 months were excluded. People with complications of diabetes, severe kidney, liver, or cardiovascular disease, or mental illness, and who were pregnant or preparing to become pregnant were also excluded.